Shilpa Medicare Limited (NSE:SHILPAMED)
India · Delayed Price · Currency is INR | Market Cap | 202.84B +153.8% |
| Revenue (ttm) | 16.83B +28.0% |
| Net Income | 2.97B +167.6% |
| EPS | 15.20 +167.4% |
| Shares Out | n/a |
| PE Ratio | 68.22 |
| Forward PE | 62.99 |
| Dividend | 0.60 (0.06%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 69,931 |
| Open | 1,035.80 |
| Previous Close | 1,037.70 |
| Day's Range | 1,026.80 - 1,044.80 |
| 52-Week Range | 259.50 - 1,075.00 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 881.25 (-15.24%) |
| Est. Earnings | Nov 6, 2026 |
About Shilpa Medicare
Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, d... [Read more]
Financial Performance
In fiscal year 2026, Shilpa Medicare's revenue was 15.40 billion, an increase of 19.60% compared to the previous year's 12.88 billion. Earnings were 2.43 billion, an increase of 210.81%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SHILPAMED stock is "Strong Buy." The 12-month stock price target is ₹881.25, which is a decrease of -15.24% from the latest price.
News
Shilpa Medicare partners with Orion for nivolumab biosimilar development in Europe
Shilpa Medicare Limited's wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Finland-based Orion Corporation. The agreement focuse...
Shilpa Medicare commissions state-of-the-art ADC manufacturing facility
Shilpa Medicare Ltd, through its subsidiary Shilpa Biologicals Ltd, has announced the commissioning of a state-of-the-art Antibody–Drug Conjugate (ADC) GMP Manufacturing Facility in Dharwad, India. Th...
Shilpa Medicare and Gate2brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy
Business Wire IndiaShilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focuse...
Shilpa Medicare subsidiary invests €7 million for 30.4% stake in Gate2Brain
Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited, has announced a strategic equity partnership with Gate2Brain, S.L., a biotechnology firm based in Barcelona. The partnersh...
Shilpa Medicare Q4 Results: Net profit jumps over 7x to Rs 108 crore, revenue up 32%
Shilpa Medicare reported a sharp rise in earnings for the fourth quarter, driven by strong revenue growth, improved operating performance, and a favourable one-time gain. The pharmaceutical company po...
Pharma sector stocks today, April 6: Shilpa Medicare down 3.07%, Ipca Labs decline 2.42%, Sun Pharma falls 1.42%
Indian pharma sector stocks traded mostly lower in early deals on April 6, 2026, with the majority of listed names showing declines of 0.2% to over 3% around 9:30-9:40 AM…
Pharma sector stocks today, March 24: Shilpa Medicare jumps 3.28%, Glenmark Pharma up 1.36%, Laurus Labs gain 1.65%
The Indian pharmaceutical sector showed mixed movements in early trading, as of approximately 9:51 AM IST on March 24, 2026. The S&P BSE Healthcare Index stood at 41,630.4, reflecting a…
Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%,
The pharmaceutical sector in India showed mixed performance on March 6, 2026, during early trading hours. Data from around 9:46 AM to 9:50 AM IST indicated the S&P BSE HEALTHCARE…
Shilpa Medicare signs strategic licensing agreement with SteinCares to commercialize biosimilar in Latin America
Shilpa Medicare Limited has expanded its global biologics footprint after its subsidiary, Shilpa Biologicals Pvt. Ltd., entered into a strategic...
Pharma sector stocks today, Feb 9: Marksans Pharma up 5%, Shilpa Medicare jumps 6%, Glenmark rises 1.83%
The Indian pharma sector showed mixed intraday movements on February 9, 2026, amid broader market gains driven by positive global...
Shilpa Medicare Q3 Results: Revenue jumps 28.3% YoY to Rs 409.73 crore, net profit up 40.3%
Shilpa Medicare delivered a strong year-on-year performance in the third quarter ended 31 December 2025, with healthy growth across both...
Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92%
The pharma sector displayed mixed performance in early trading on February 4, 2026. While some stocks recorded gains, others faced...
Pharma sector stocks today, Feb 1: Shilpa Medicare rally 8%, Sun Pharma up 3%, Aurobindo Pharma falls 2.21%
The Indian pharmaceutical sector showed mixed performance as of February 1, 2026, around 10 AM IST, with many stocks trading...
Shilpa Medicare shares in focus after subsidiary secures key US FDA orphan drug milestone
Shares of Shilpa Medicare are likely to remain in focus after the company informed stock exchanges that its material subsidiary,...
Shilpa Medicare receives Initial Authorization for Rotigotine transdermal patch in European
Shilpa Medicare Limited, headquartered in Raichur, Karnataka, has announced that it has received Initial Authorization from European regulatory authorities recommending...
Shilpa Medicare launches world’s first NODUCA Therapy for MAFLD after CDSCO approval
Shilpa Medicare has rolled out a breakthrough treatment for metabolic dysfunction-associated fatty liver disease (MAFLD) with the launch of NODUCA™...
Shilpa Medicare Q2 Results: Net profit jumps 144% YoY to Rs 44 crore, revenue up 7.6%
Shilpa Medicare has announced a strong set of Q2 numbers, showing a sharp improvement in profitability along with steady revenue...
Shilpa Medicare shares jump nearly 3% after positive Phase 3 results for once-weekly Ondansetron injection OERIS™
Shares of Shilpa Medicare Ltd gained nearly 3% on Monday, hitting an intraday high of Rs 385.80 before settling at...
Shilpa Medicare announces positive Phase 3 results for OERIS™ — once-weekly Ondansetron injection for chemotherapy-induced nausea and vomiting
Shilpa Medicare Limited has announced the successful completion of its Phase 3 clinical trial for OERIS™ (Ondansetron Extended-Release Injection), a...
Shilpa Pharma Lifesciences wins EcoVadis Gold Medal for excellence in sustainability
Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited, has been awarded the prestigious Gold Medal by EcoVadis...
Shilpa Medicare sells 31% stake in Sravathi Advance Process Technologies for ₹49.6 crore; brings in new strategic investors
Shilpa Medicare Limited announced that it has entered into a Share Purchase Agreement and Shareholders’ Agreement with Ash Ingredients Inc....
Shilpa Medicare sells 31% stake in Sravathi Advance Process Technologies for Rs 49.6 crore
Shilpa Medicare Limited has announced that it has entered into a Share Purchase Agreement and Shareholders’ Agreement dated October 27,...
Blood donation camp held on birthday
Raichur: KH Honneshaiah, head of operations at Shilpa Medicare, emphasised the importance of blood donation, stating that it has the potential to save.
Shilpa Medicare shares jump over 4% as EMA grants nod for Rivaroxaban Orodispersible Films
Shares of Shilpa Medicare Limited surged 4.22% on Tuesday, September 23, trading at ₹853.00 on the NSE. The company’s market capitalization stood at ₹83.42 billion. The rally came after the pharma com...
Shilpa Medicare jumps another 2.5% as stock extends rally on Saudi JV announcement
Shares of Shilpa Medicare surged another 2.5% in Wednesday’s session, taking their two-day rally to over 5%, after the company announced plans to set up a new joint venture in Saudi Arabia with Pharma...